Elite Pharmaceuticals, Inc. Interest Income (Expense), after Provision for Loan Loss
Elite Pharmaceuticals, Inc. (ELTP) reported Interest Income (Expense), after Provision for Loan Loss of $857.38 thousand for the 12-month period ending 2022-03-31, per its 10-K filed 2023-06-29.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseAfterProvisionForLoanLoss · last filed 2023-06-29
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for the quarter ending 2022-03-31 was $0.00.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for the quarter ending 2021-12-31 was $0.00.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for the quarter ending 2021-09-30 was $2.03K.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for the quarter ending 2021-06-30 was $855.35K, a 9.62% decline year-over-year.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for fiscal 2022 was $857.38K, a 9.17% decline from fiscal 2021.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for fiscal 2021 was $943.91K.
- Elite Pharmaceuticals, Inc. interest income (expense), after provision for loan loss for fiscal 2020 was -$2.00K.
| Period end | Interest Income (Expense), after Provision for Loan Loss 3 month | Interest Income (Expense), after Provision for Loan Loss 6 month | Interest Income (Expense), after Provision for Loan Loss 6 month as first filed | Interest Income (Expense), after Provision for Loan Loss 9 month | Interest Income (Expense), after Provision for Loan Loss 9 month as first filed | Interest Income (Expense), after Provision for Loan Loss 12 month |
|---|---|---|---|---|---|---|
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-29 | $0.00 derived: sum of 2 quarters · filed 2023-06-29 | $2.03K derived: sum of 3 quarters · filed 2023-06-29 | $857.38K 10-K · filed 2023-06-29 | ||
| 2021-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-14 | $2.03K derived: sum of 2 quarters · filed 2023-02-14 | $857.38K 10-Q · filed 2023-02-14 | $854.88K derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-09-30 | $2.03K 10-Q · filed 2022-11-14 | $857.38K 10-Q · filed 2022-11-14 | $854.88K derived: sum of 3 quarters · filed 2022-11-14 | $854.88K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $855.35K 10-Q · filed 2022-08-15 | $852.85K derived: sum of 2 quarters · filed 2022-08-15 | $852.85K derived: sum of 3 quarters · filed 2022-08-15 | $850.35K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$2.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-29 | -$2.50K derived: sum of 2 quarters · filed 2022-06-29 | -$5.00K derived: sum of 3 quarters · filed 2022-06-29 | $943.91K 10-K · filed 2022-06-29 | ||
| 2020-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | -$2.50K derived: sum of 2 quarters · filed 2022-02-14 | $946.41K 10-Q · filed 2022-02-14 | $943.91K 10-Q · filed 2021-02-16 | $943.91K derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | -$2.50K 10-Q · filed 2020-11-16 | $946.41K 10-Q · filed 2021-11-15 | -$2.50K 10-Q · filed 2020-11-16 | $943.91K derived: sum of 3 quarters · filed 2021-08-16 | $943.91K derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-06-30 | $946.41K 10-Q · filed 2021-08-16 | $946.41K derived: sum of 2 quarters · filed 2021-08-16 | $946.41K derived: sum of 3 quarters · filed 2021-08-16 | $944.41K derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14 | $0.00 derived: sum of 2 quarters · filed 2021-06-14 | -$2.00K derived: sum of 3 quarters · filed 2021-06-14 | -$2.00K 10-K · filed 2021-06-14 | ||
| 2019-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | -$2.00K derived: sum of 2 quarters · filed 2021-02-16 | -$2.00K 10-Q · filed 2021-02-16 | |||
| 2019-09-30 | -$2.00K 10-Q · filed 2020-11-16 | -$2.00K 10-Q · filed 2020-11-16 |